Related Experiment Video

Updated: Oct 14, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K

Cisplatin, Neoadjuvant Chemotherapy and Bladder Cancer

Harry Herr1, Mark Soloway1

  • 1Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, Memorial Cancer Institute, Aventura, FL.

Urology
|November 5, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.9K

Related Experiment Videos

Last Updated: Oct 14, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.9K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

292
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
292
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

385
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
385

Articles linked to this work by shared authors, journal, and citation graph.

Comprehensive clinical and genomic analysis of early onset cancer of the bladder and upper urinary tract.

Journal of the National Cancer Institute·2026

Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus.

Nature reviews. Urology·2026

Neoadjuvant Chemotherapy With Transurethral Resection for Bladder Preservation: 15-Year Follow-Up of the Retained Bladder.

The Journal of urology·2025

Prospective health-related quality of life in women undergoing radical cystectomy and urinary diversion.

BJU international·2025

Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG).

European urology oncology·2024

Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.

European urology·2024

Convergent Validity of Stamey's Incontinence Scoring System in Assessing Post-Prostatectomy Urinary Incontinence.

Urology·2026

Urinary Biomarkers in Childhood Cancer Survivors with Lower Urinary Tract Dysfunction.

Urology·2026

Item Level Analysis of Patient-Reported Outcomes After Ureteroscopy for Kidney Stones- Plan Your Chores, Cancel Your Plans.

Urology·2026

Trends in Urodynamic Study Claims Billed by Physicians and Advanced Practice Providers in the United States between 2010 and 2024.

Urology·2026

Infectious disease referrals optimize long-term management of women with recurrent urinary tract infections.

Urology·2026

Validation and testing of an in vitro model to study medical treatments for anterior urethral stricture disease: assessing the potential efficacy of phosphodiesterase-4 (PDE4) inhibition and testosterone.

Urology·2026

Neoadjuvant chemotherapy in women with triple-negative breast cancer: Real world results from western Kenya.

The oncologist·2026

A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Regulating Triplet Energy Level and Intramolecular Motion: An Aggregation-Induced Emission BODIPY for Near-Infrared Type I Photodynamic/Photothermal Synergistic Therapy.

ACS applied materials & interfaces·2026

The hormetic landscape: from evolutionary origination to mechanistic pathways in therapeutics.

Cell cycle (Georgetown, Tex.)·2026

Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol.

BJU international·2026

Clinical Outcomes of Gradual Corticosteroid Tapering for Immune Checkpoint Inhibitor-Induced Liver Injury.

Hepatology research : the official journal of the Japan Society of Hepatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us